ArticleDiabetes, obesity & metabolism2026
Sodium glucose co-transporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors and the risk of ventricular arrhythmia among patients with type 2 diabetes: A population-based cohort study.
Article in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Sodium Glucose Co-Transporter 2 Inhibitors and Ventricular Arrhythmias in Patients with Type 2 Diabetes: A Systematic Review of Observational Studies.Drug safety · 2026Pooled it
- Sodium glucose co-transporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors and the risk of ventricular arrhythmia among patients with type 2 diabetes: A population-based cohort study.Diabetes, obesity & metabolism · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsTo determine whether sodium glucose co-transporter 2 inhibitors (SGLT2i) use, compared with dipeptidyl peptidase-4 inhibitors (DPP4i) use, is associated with the risk of ventricular arrhythmias (VA) among patients with type 2 diabetes. MATERIALS AND
methodsWe conducted a population-based cohort study using a prevalent new-user design and data from the United Kingdom Clinical Practice Research Datalink Aurum, linked to hospitalisation and vital statistics data. SGLT2i users were matched to DPP4i users on diabetes treatment intensity, duration of prior DPP4i use, calendar time, sex, age, and time-conditional propensity score. Cox models estimated the hazard ratio (HR) and corresponding 95% confidence intervals (CI) for VA with SGLT2i vs. DPP4i use. Secondary analyses stratified by SGLT2i user type. Secondary outcomes included fatal VA and cardiac arrest.
resultsAmong 88 516 matched patients, 385 VA events occurred over a mean follow-up of 0.86 years (25.3 per 10 000 person-years). Overall, SGLT2i use was not associated with the risk of VA (HR: 0.88, 95% CI: 0.71-1.07). There was no association among incident new users (HR: 0.98, 95% CI: 0.76-1.27) but SGLT2i use was associated with a lower risk among prevalent new users (HR: 0.65, 95% CI: 0.46-0.92). SGLT2i use was associated with a lower risk of cardiac arrest (HR: 0.64, 95% CI: 0.49-0.83); our analysis of fatal VA was inconclusive due to sparse data (HR: 1.76, 95% CI: 0.47-6.64).
conclusionsSGLT2i use was not associated with the risk of VA among patients with type 2 diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.